Journals / Türk Toraks Dergisi / 2011 / Cilt: 12 - Sayı: 3

Relationship of systemic antiinflammatory markers and functional parameters in chronic obstructive pulmonary disease

Kronik obstrüktif akciğer hastalığında fonksiyonel paramatrelerle sistemik antiinflamatuar belirteçlerin ilişkisi

Pages
88–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This may be due to incomplete systemic response to local disorders as well as the attempts of antioxidant systems to maintain an equilibrium resembling that in healthy individuals. (Tur Toraks Der 2011; 12: 88-93)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Airway inflammation and oxidative stress biomarkers increase in chronic obstructive pulmonary disease (COPD) and this is thought to be related to faster decrease in lung functions.
📊
Key Findings & Data:Pulmonary function test parameters were evaluated. 6-minute walk test (6MWT) and dyspnea severity were recorded.
💡
Conclusion & Impact:This may be due to incomplete systemic response to local disorders as well as the attempts of antioxidant systems to maintain an equilibrium resembling that in healthy individuals. (Tur Toraks Der 2011; 12: 88-93)
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Airway inflammation and oxidative stress biomarkers increase in chronic obstructive pulmonary disease (COPD) and this is thought to be related to faster decrease in lung functions. Systemic markers of oxidative stress include nitric oxide (NO) and malonyl dialdehyde (MDA), while antioxidant markers are erythrocyte superoxide dismutase (SOD) and gluthathionperoxidase (GSH-Px). We investigated the relationship between levels of systemic oxidative/antioxidant markers and functional parameters. Material and Method: Fifty-one COPD patients without any systemic inflammation were included in the study. Pulmonary function test parameters were evaluated. 6-minute walk test (6MWT) and dyspnea severity were recorded. Twelve healthy persons in a control group were also included in the study. Venous blood specimens of the patients and the control group were collected and serum NO, MDA and erythrocyte SOD, GSHPx levels were measured. Results: Mean age of the patients were 62.94±10.56 years. When the control group and COPD patients were compared; MDA (p<0.001), NO (p=0.012) and GSH-Px (p=0.012) were significantly higher in the control group than COPD patients. However, when the age factor was controlled, only MDA(p=0.017) was found higher in the control group. As forced expiratory volume in 1st second (FEV1) decreased; NO, SOD, MDA and GSH-Px increased, although there was no statistical significance. Like FEV1, 6MWT and dyspnea severity by VAS did not show any statistical significance with the parameters investigated. Conclusion: From the results, we could not observe the reflections of oxidant/antioxidant imbalance on functional parameters in COPD. This may be due to incomplete systemic response to local disorders as well as the attempts of antioxidant systems to maintain an equilibrium resembling that in healthy individuals. (Tur Toraks Der 2011; 12: 88-93)

Özet

Amaç: Kronik obstrüktif akciğer hastalığında (KOAH) hava yolu inflamatuar ve oksidatif stres belirteçlerinin arttığı ve bunun akciğer fonksiyonlarında daha hızlı düşme ile ilişkili olduğu düşünülmektedir. Oksidatif stresin sistemik belirteçleri arasında nitrik oksit (NO) ve malonil dealdehit (MDA), antioksidan belirteçler arasında da eritrosit superoksit dismutaz (SOD) ve glutatyon peroksidaz (GSH-Px) yer almaktadır. Çalışmamızda KOAH’lı hastalardaki sistemik oksidan ve antioksidan belirteç düzeylerinin fonksiyonel parametrelerle ilişkisini araştırdık. Gereç ve Yöntem: KOAH tanılı ve bilinen sistemik inflamatuar ek hastalığı olmayan 51 hasta çalışmaya alındı. Tüm olguların solunum fonksiyon testleri değerlendirildi, 6 dakika yürüme testi (6DYT) ve dispne derecelendirilmesi (VAS) yapıldı. Çalışmaya 12 sağlıklı kontrol da dahil edildi. Hasta ve kontrol grubunda, venöz kanda eritrositlerde SOD, GSH-Px ve serumda NO, MDA düzeyleri bakıldı. Bulgular: Hastaların yaş ortalaması 62.94±10.56 yıl olarak bulundu. Kontrol ve hasta grubu arasında MDA (p<0.001), NO (p=0.012) ve GSH-Px (p=0.012) açısından anlamlı fark mevcuttu; her üç belirteç de kontrol grubunda KOAH grubuna göre yüksekti ancak yaş faktörüne göre düzeltme yapıldığında sadece MDA (p=0.017) kontrol grubunda daha yüksek saptandı. 1. saniyede zorlu ekspiratuvar volüm (FEV1) düştükçe NO, SOD, MDA ve GSH-Px istatistiksel anlamlı olmasa da artmaktaydı. FEV1 gibi 6DYT ve VAS ile de araştırılan parametrelerin hiçbirisi ile istatistiksel anlamlı ilişkisi yoktu. Sonuç: Çalışmamızda KOAH’ta oksidan ve antioksidan denge bozukluğunun fonksiyonel parametrelere yansımasını saptayamadık. Bu durum, lokal bulguların sistemik olarak tam yansımaması yanında KOAH’ta antioksidanların sağlıklı kişilerdekine benzer bir denge oluşturmaya çalışmasına bağlı olabilir. (Tur Toraks Der 2011; 12: 88-93)

🔖

Cite This Article

SATAR, S., ALPAYDIN, A. Ö., VAR, A., ŞAKAR, A. C., ÇELİK, P., YORGANCIOĞLU, A. (2011). Relationship of systemic antiinflammatory markers and functional parameters in chronic obstructive pulmonary disease. Türk Toraks Dergisi, Cilt: 12 - Sayı: 3, 88–93. https://ajindex.com/articles/329541

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med 2006;3:442. [CrossRef] 2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstuctive pulmonary disease 2006. www.goldcopd.org. 3. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005;99:670-82. [CrossRef] 4. Decramer M, De Benedetto F, Del Ponte A, Marinari S. Systemic effects of COPD. Respir Med 2005;99:3-10. 5. Agusti A. Chronic Obstructive Pulmonary Disease: A systemic disease. Proc Am Thorac Soc 2006;3:478-81. [CrossRef] 6. van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000;15:915-21. 7. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60. [CrossRef] 8. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999;159:S1-40. 9. MacNee W, Wiggs B, Belzberg AS, Hogg JC. The effect of cigarette smoking on neutrophil kinetics in human lungs. N Engl J Med 1989;321:924-8. [CrossRef] 10. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004. [CrossRef] 11. Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 2005;29:23-32. [CrossRef] 12. Kluchova Z, Petrasova D, Joppa P, Dorková Z, Tkácová R. The association between oxidative stress and obstructive lung impairment in patients with COPD. Physiol Res 2007;56:51-6. [CrossRef] 13. Redington AE. Modulation of nitric oxide pathways: Therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur J Pharmacol 2006;8:263-76. [CrossRef] 14. Kılıçturgay K. Sitokinler. In: Kılıçturgay (ed). Immunolojiye Giriş. Bursa. Nobel Tıp Kitabevi 1994:72-83. 15. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12. [CrossRef] 16. Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. Nature 1994;372:546-8. [CrossRef] 17. Williams G, Brown T, Becker L, Prager M, Giroir BP. Cytokineinduced expression of nitric oxide synthase in C2C12 skeletal muscle myocytes. Am J Physiol 1994;267:1020-5. [Cross